



(11)

EP 0 998 941 B9

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see page(s) 8
INID code(s) 56

(51) Int Cl.:

A61K 38/17 (2006.01) **A61K 39/395** (2006.01)
A61K 38/20 (2006.01) **A61K 38/19** (2006.01)

(48) Corrigendum issued on:

24.01.2007 Bulletin 2007/04

(86) International application number:

PCT/JP1998/003161(45) Date of publication and mention
of the grant of the patent:**21.06.2006 Bulletin 2006/25**

(87) International publication number:

WO 1999/003493 (28.01.1999 Gazette 1999/04)(21) Application number: **98931102.2**(22) Date of filing: **14.07.1998**

(54) USE OF MIDKINE OR OF ANTI-MIDKINE ANTIBODIES

VERWENDUNG VON MIDKIN ODER VON ANTI-MIDKIN ANTIKÖRPER

UTILISATION DE MIDKINE ET D'ANTICORPS ANTI-MIDKINE

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **14.07.1997 JP 20532097****14.07.1997 JP 20533297**

(43) Date of publication of application:

10.05.2000 Bulletin 2000/19(73) Proprietor: **Muramatsu, Takashi
Nagoya-shi, Aichi 468-0021 (JP)**

(72) Inventors:

- **MURAMATSU, Takashi
Tenpaku-ku,
Nagoya-shi, Aichi 468-0021 (JP)**
- **TAKADA, Tohru
Nagoya University
Dept. Biochemistry
Nagoya-shi,
Aichi 466-0065 (JP)**
- **TORIYAMA, Kazuhiro
Nagoya University
Nagoya-shi
Aichi 466-0065 (JP)**
- **MURAMATSU, Hisako
Tenpaku-ku,
Nagoya-shi, Aichi 468-0021 (JP)**

(74) Representative: **Vossius & Partner**

**Siebertstrasse 4
81675 München (DE)**

(56) References cited:

EP-A- 0 535 336	EP-A- 0 569 703
EP-A- 0 937 461	WO-A-94/28889
JP-A- 8 277 224	JP-A- 63 088 127
JP-T- 6 507 635	US-A- 5 629 284

- **SPRINGER T A: "Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm." CELL. UNITED STATES 28 JAN 1994, vol. 76, no. 2, 28 January 1994 (1994-01-28), pages 301-314, XP002030607 ISSN: 0092-8674**
- **KOJIMA S ET AL: "Midkine enhances fibrinolytic activity of bovine endothelial cells." THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 21 APR 1995, vol. 270, no. 16, 21 April 1995 (1995-04-21), pages 9590-9596, XP002273454 ISSN: 0021-9258**
- **KODELJA V ET AL: "DIFFERENCES IN ANGIOGENIC POTENTIAL OF CLASSICALLY VS ALTERNATIVELY ACTIVATED MACROPHAGES" IMMUNOBIOLOGY, FISCHER, STUTTGART, DE, vol. 197, no. 5, November 1997 (1997-11), pages 478-493, XP001089691 ISSN: 0171-2985**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- TOHRU TAKADA, "Midkine, a Retinoic Acid-Inducible Heparin-Binding Cytokine, is a Novel Regulator of Intracellular Calcium in Human Neutrophils", **BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS**, Vol. 241, No. 3, (1997), p. 756-761, XP002911185
- TOHRU TAKADA, "Midkine, a Retinoic Acid-Inducible Heparin-Binding Cytokine in Inflammatory responses: Chemotactic Activity to Neutrophils and Association with Inflammatory Synovitis", **J. BIOCHEM.**, Vol. 122, No. 2, (1997), p. 453-458, XP002911186
- KENJU HIRAMATSU, "Midkine Induces Histamine Release from Mast Cells and the Immediate Cutaneous Response", **BIOCHEMISTRY AND MOLECULAR INTERNATIONAL**, Vol. 44, No. 3, (1998), p. 453-462, XP002911187
- XUE-ZHI SUN, "Midkine, a New Heparin-Binding Growth/Differentiation Factor: Expression and Distribution During Embryogenesis and Pathological Status", **CONGENITAL ANOMALIES**, Vol. 38, No. 1, (1998), p. 25-38, XP002911188

Description**Technical Field**

[0001] The present invention relates to the use of midkine or an anti-midkine antibody as an active ingredient for the preparation of pharmaceutical agents for treating neutrophilic functional disorders or inflammatory diseases, respectively.

Background Art

[0002] Neutrophils, which is a type of granulocytes, have migratory, phagocytic, and microbicidal activities, and play important roles in biological protection against infectious agents such as bacteria or fungi. There are some diseases associated with neutrophils.

[0003] Neutrophilic functional disorders, in which one or more of the above-mentioned biological activities of neutrophils are impaired, include, for example, lazy-leukocyte (chemotaxis-deficient leukocyte) syndrome, one of the neurotaxis deficient diseases. In patients affected with this syndrome, neutrophils are markedly decreased in number in the peripheral blood, and their migratory activity is impaired, although they are present at a normal level in the bone marrow. Patients suffering from neutrophilic functional disorders are very few, and drugs applicable to the disorders are so far not commercially available.

[0004] Another example of the diseases associated with neutrophils is inflammatory diseases. Inflammatory reaction is a biological protection to tissue damages caused by inflammatory stimulation (e.g., foreign bodies such as bacteria or others, and physicochemical stimulation, etc.). The inflammatory reaction basically removes harmful stimulation from the living body and restores local tissue structures and functions. The activated inflammatory system is, however, toxic to normal tissues and cells, and the strongly expressed inflammatory reaction should be suppressed.

[0005] The inflammatory reaction includes three major processes; 1) increment of blood supply to infected sites; 2) enhancement of vascular permeability due to the reaction in vascular endothelial cells; and 3) mobilization of leukocytes, specifically, neutrophils and some macrophages, from capillaries to tissues, and subsequent migration to infected sites. These processes result in accumulation and infiltration of neutrophils as well as macrophages at their target sites. Thus repressing the neutrophilic functions has been believed to be effective for controlling the inflammatory reaction.

[0006] Various anti-inflammatory drugs have been developed. They are categorized into two groups, non-specific anti-inflammatory drugs (steroidal anti-inflammatory drugs and non-steroidal anti-inflammatory drugs) and specific anti-inflammatory drugs (anti-rheumatic drugs, anti-podagric drugs, immunosuppressants, etc.). Analgesic and anti-inflammatory drugs (non-steroidal anti-in-

flammatory drugs, NSAIDs) are used mainly, and anti-rheumatic drugs (disease-modifying anti-rheumatic drugs, DMARDs) and steroid drugs are used secondarily, in chemotherapy for rheumatoid arthritis (RA). However, NSAIDs cause acute gastric mucosal lesions (AGML), and are thus often used in the form of prodrugs to avoid AGML.

[0007] Recently, midkine (MK) has been identified as a heparin-binding polypeptide with the molecular weight of 13kDa and a retinoic acid-inducible gene product. Reported midkine functions include maintaining and differentiating embryonic nerve cells and enhancing neurite extension; promoting division of specific cell lines (Muramatsu, H. et al., Biochem. Biophys. Res. Commun. 177: 652-658, 1991; and Michikawa, M. et al., J. Neurosci. Res. 35: 530-539, 1993; Muramatsu, H. et al., Dev. Biol. 159: 392-402, 1993); regulating embryonic development (Kadomatsu, K. et al., J. Cell. Biol. 110: 607-616, 1990; Mitsiadis, T. A. et al., Development 121: 37-51, 1995); etc. Furthermore, anti-midkine antibody reportedly inhibits dentition *in vitro* (Mitsiadis, T.A. et al., J. Cell. Biol. 129: 267-281, 1995).

[0008] It has been revealed that midkine plays crucial roles in restoration of damaged tissues and some diseases. The expression patterns of midkine were investigated in various human carcinomas. The studies revealed that midkine expression is elevated in various cancers including stomach cancer, colon cancer, pancreatic cancer, lung cancer, thoracic cancer, and liver cancer (Tsutsui, J. et al., Cancer Res. 53: 1281-1285, 1993; Aridome, K. et al., Jap. J. Cancer Res. 86: 655-661, 1995; and Garver, R.I. et al., Cancer 74: 1584-1590, 1994). The high-level expression of midkine correlates with unfavorable prognoses in patients affected with neuroblastoma (Nakagawara, A. et al., Cancer Res. 55: 1792-1797, 1995). Midkine accumulates in senile plaques of most patients with Alzheimer's disease (Yasuhara, O. et al. Biochem. Biophys. Res. Commun. 192: 246-251, 1993). Midkine is expressed in regions with edema at early stages of cerebral infarction (Yoshida, Y. et al., Dev. Brain Res. 85: 25-30, 1995). These findings indicate that midkine may be associated with restoration of damaged tissues and tissue abnormalities that are signs of some diseases.

Disclosure of the Invention

[0009] An objective of the present invention is to provide novel means for controlling neutrophilic functions, specifically, for treating neutrophilic functional disorders, for enhancing chemotaxis and haptotaxis of neutrophils, and treating inflammatory diseases.

[0010] A recent report (Kojima, S. et al., J. Biol. Chem. 270: 9590-9596, 1995) has shown that midkine enhances the activity of plasminogen activator in vascular endothelial cells and also enhances the fibrinolytic activity that is important in the migration of cells to inflammatory sites and in cell migration in cancer cell infiltration and

angiogenesis. It has also been clarified that midkine triggers leukocyte mobilization at the initial stage of inflammation (Timothy, A. S. Cell 76:301-314, 1994). Based on these reports, the present inventors analyzed the expression of midkine in inflammation models associated with rheumatoid arthritis (RA) and osteoarthritis (OA). The results indicate that the level of midkine was elevated in the inflammatory states closely associated with neutrophils. The present inventors also examined effect of midkine on neutrophilic migration and found that a matrix-bound midkine stimulates neutrophilic migration.

[0011] Furthermore, based on the findings of the close relationship between midkine and neutrotaxis as well as between midkine and inflammation, the present inventors have found that the diseases associated with neutrophilic functions, including, for example, neutrophilic functional disorders and inflammatory diseases, can be treated by controlling biological activities of neutrophils using midkine or its inhibitors. The present invention relates to the <claim 1> or to the <claim 8>.

[0012] More specifically, herein described is

- (1) the use of midkine as an active ingredient for the preparation of an agent that stimulates neutrophilic chemotaxis,
- (2) the use of (1), wherein the neutrophilic chemotaxis is based on haptotactic mechanism,
- (3) the use of midkine as an active ingredient for the preparation of an agent for treating a neutrophilic functional disorder,
- (4) the use of an anti-midkine antibody as an active ingredient for the preparation of an agent for treating an inflammatory disease,
- (5) the use of (4), wherein the inflammatory disease is rheumatoid arthritis or osteoarthritis,

[0013] As used herein, the "agents for treating neutrophilic functional disorders" include not only the agents for treating neutrophilic functional disorders but also agents for relieving unpleasant conditions of neutrophilic functional disorders. Similarly, the "agents for treating inflammatory diseases" used herein include not only the agents for treating inflammatory diseases but also agents for relieving unpleasant conditions of inflammatory diseases.

[0014] Agents containing midkine as an active ingredient of the present invention can stimulate neutrophilic chemotaxis. Chemotaxis means a process that leukocytes including neutrophils migrate to inflammatory sites (infected sites) along a concentration gradient of a chemotactant factor and accumulate there. After the migration, neutrophils adsorb microorganisms such as bacteria, uptake (phagocytosis), and eliminate them by various mechanisms. Chemotaxis is an important step for neu-

trophils to perform their own functions. There are two migration mechanisms, chemotactic mechanism and haptotactic mechanism. In the chemotactic mechanism, a chemotactant factor is a humoral factor that can diffuse from the place where it is produced, namely where its concentration is highest. Cells migrate toward the place where the chemotactant factor level is high. In contrast, in the haptotactic mechanism, a chemotactant factor attaches vascular endothelial cells or extracellular matrices, and cells migrate to the tissue with the highest density of the chemotactant factor. The present inventors demonstrated that midkine acts based on not the chemotactic mechanism but the haptotactic mechanism.

[0015] The agents of the present invention comprising midkine as an active ingredient can be used for treating neutrophilic functional disorders. Major neutrophilic functions are migratory, phagocytic, and microbicidal activities. Neutrophilic functional disorders are defined as a state in which one or more of these three activities are impaired. An example of neutrophilic functional disorders is lazy-leukocyte (chemotaxis-deficient leukocyte) syndrome that is a neutrotaxis deficient disease. As described above, the present inventors have revealed that midkine stimulates neutrophilic migration, indicating that the impaired functions of neutrophils that are unable to migrate can be restored by acting midkine on them.

[0016] If desired, the agents of this invention for treating neutrophilic functional disorders can be used together with other factors which can enhance neutrophilic functions, including, for example, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-8 (IL-8), macrophage colony-stimulating factor (M-CSF), and the like.

[0017] Midkine used in the present invention can be derived from any mammalian species including human (see, Examples in Unexamined Published Japanese Patent Application No. (JP-A) Hei 9-95454 and), mouse (Kadomatsu, K., et al., Biochem. Biophys. Res. Commun., 151: 1312-1318, 1988), rat, etc. Midkine used in the present invention includes intact midkine polypeptide, and its derivatives and homologues having midkine biological activities in which one or more amino acid residues of partial peptide sequences of the intact polypeptide are substituted or deleted. The midkine polypeptide of the present invention may be glycosylated or unglycosylated.

[0018] Agents containing an anti-midkine antibody used in the present invention as an active ingredient can be used for treating inflammatory diseases. The present inventors have demonstrated that midkine is present at high concentrations in inflammatory sites of patients with inflammatory diseases. Inflammation is closely associated with neutrophilic migration as is well known in the art. Accordingly, it is presumed that the suppressive effect of midkine inhibitors on neutrophilic motility can treat inflammatory diseases. Inflammatory diseases mean a disease with clinical manifestation of inflammation in any cases in which the disease results in or results from in-

flammation. Inflammation in higher animals is characteristically caused by a series of reactions in the microcirculation system in response to stimulation. In ordinary inflammation, microvessels transiently constrict, and then dilate, and the capillary bed, which is closed in an ordinary state of tissues, opens and increases blood supply. In addition, intracellular spaces between vascular endothelial cells in venular regions become wider and plasma components effuse therethrough to tissues (vasopermeability enhancement). The vasopermeability enhancement occurs in a biphasic fashion: the first-phase reaction is a weak reaction triggered by histamine or serotonin, which is called the immediate permeation; and the second-phase reaction is major vasopermeation in inflammation, which is called the delayed permeation. Polymorphonuclear leukocytes, monocytes (called macrophages after emigrating to tissues), lymphocytes, etc. emigrate through the venular region to tissues. Activators produced by these plasma components and cells enhance the proliferation of tissue cells and stimulate tissue restoration. This process is known to manifest as rubor, dolor, calor, and tumor. Inflammation, which is basically a local biological protective reaction, can also be tissue-toxic, and therefore functional impairment is recognized as one of main symptoms of inflammation. Inflammation reaction comprises dynamic processes of a complex reaction of alteration, circulatory disturbance, and proliferation of local tissues and cells. Inflammatory conditions are classified into three classes, alterative, exudative, and proliferative inflammations depending on the symptoms that strongly manifest. The conditions are also classified into acute and chronic inflammations with regard to the course of inflammation. Inflammation diseases include, for example, rheumatoid arthritis (RA) and osteoarthritis (OA).

[0019] The antibody may be a polyclonal or monoclonal antibody.

[0020] Polyclonal antibody against midkine can be prepared as follows. A solution of recombinant human midkine prepared by an appropriate method is mixed with an equal volume of Freund's complete adjuvant (FCA) to obtain a homogeneous emulsion. The emulsion is injected subcutaneously at approximately 10 sites per a rabbit (New Zealand White, from 2,500 to 3,000 g). The injection sites are disinfected with cotton containing 70% ethanol. After this first immunization, Freund's incomplete adjuvant (FIA) is used as an adjuvant instead of FCA in the second and later immunization. Immunization is performed every two weeks. One week after the third immunization, blood is sampled from the rabbit, centrifuged at 1,600 rpm at 4°C to obtain serum, which is examined for the titer of anti-midkine antibody. When the antibody titer is increased to a satisfactory level, then the entire blood is collected from the rabbit after the fourth or fifth immunization. Serum is obtained from the entire blood by centrifugation at 1,600 rpm at 4°C as described above. The anti-midkine antibody is purified from the serum using protein A. The antibody is then further purified

by affinity column chromatography using a human midkine polypeptide-bound column. Anti-midkine polyclonal antibody can be prepared through the procedures described above. Animals to be immunized are not limited to rabbits. Anti-midkine antibodies are obtained from various animal species immunized by essentially the same method as described above.

[0021] Monoclonal antibody against midkine can be prepared by the method reported by Kohler and Milstein (Kohler, G. and Milstein, C., *Nature* 256: 495-497, 1975).

[0022] Anti-midkine antibodies include humanized antibodies (Noguchi, H., and Azuma, T., Preparation of chimeric antibodies by antibody engineering and its application, *Medical Immunol.* 22: 628-638, 1991; Noguchi, H., Rationale and clinical application of chimeric antibodies and humanized antibodies, *Igakunoayumi* 167: 457-462, 1993; and Nakatani, T., and Noguchi, H., Humanization of antibodies, *Pharmacia* 33: 24-28, 1997), human antibodies (Chothia, C. et al., *Nature*, 324: 877, 1989; Roguska, M. L., et al., *Proc. Natl. Acad. Sci. U.S.A.*, 91: 969, 1994; Winter, G. et al., *Annu. Rev. Immunol.*, 12: 433, 1994; and Lonberg, N. et al., *Nature*, 368: 856, 1994), chimeric antibodies (Morrison, S.L. et al., *Proc. Natl. Acad. Sci. U.S.A.*, 81: 6851, 1984; and Noguchi, H., and Azuma, T., *Medical Immunology*, 22: 628-638, 1991), etc.

[0023] Midkine polypeptide used as an antigen for antibody preparation may be any midkine polypeptides derived from mammalian species including human (JP-A-Hei 6-217778), mouse (Kadomatsu, K. et al., *Biochem. Biophys. Res. Commun.*, 151: 1312-1318, 1988), rat, etc.

Partial peptides derived from intact midkine and having biological activities of midkine can be used as an antigen for preparing anti-midkine antibody. Derivatives or homologues of midkine or its partial peptide, in which one or more amino acids are substituted or deleted, can also be used. Midkine polypeptide used as an antigen may be glycosylated or unglycosylated.

[0024] The agents of used in the present invention comprising midkine or an anti-midkine antibody as an active ingredient can be given to patients for stimulating chemotaxis of neutrophils, for treating neutrophilic functional disorders, or for treating inflammatory diseases.

The dose of the active ingredient may vary depending on sex, body weight, and conditions of patients. In general, it can be administered to a patient in a daily dose of from 0.1 to 1000 mg once or several times. Preferably, midkine or an anti-midkine antibody can be formulated into an aqueous solution or in an appropriate dosage form together with pharmaceutically acceptable carriers and administered intravenously, subcutaneously or intramuscularly.

Brief Description of the Drawings

[0025]

Fig. 1 is a graph showing a result of enzyme-immu-

noassay for MK polypeptide in synovial fluid. The detection limit was 9 pg/ml in this assay. The MK concentrations below the detection limit are plotted on the base line of the abscissa.

Fig. 2 depicts microphotographs of immunohistochemically stained inflammatory synovial tissue sections derived from a patient with active inflammation of rheumatoid arthritis (RA) in synovial fluid. Panel A indicates a stained section between synovial cells and a neogenetic vessel; B stained synovial parietal cells, and C stained vascular endothelial cells of a neogenetic vessel. Magnification was 104 fold in panel A; 208 fold in panels B and C.

Fig. 3 is a photograph showing a pattern of Western blot analysis of extracts from synovial tissues. Lane 1 is for the tissue with active synovitis of an OA patient; lane 2, the tissue with active synovitis of an RA patient; lane 3, the tissue of inactive synovitis; and lane 4, the synovial tissue with no histologically severe inflammation derived from a patient who underwent artificial joint replacement.

Fig. 4 is a graph showing the degree of neutrophilic migration in response to MK. MK was added into bottom wells at a predetermined concentration. After a 3-hour incubation in the presence of MK, the number of neutrophils migrated to the lower surface of the filter was counted. The average number of neutrophils migrated per optical field was plotted against the MK concentration.

Fig. 5 shows a result of checkerboard analysis for neutrophilic migration stimulated by MK. Data are represented as an average number of neutrophils migrated per optical field \pm standard deviation (n=4). The data on the crossed line are average values of the cell number per optical field in the absence of MK concentration gradient.

Fig. 6 is a graph showing the degree of MK-dependent migration of neutrophils based on haptotactic or chemotactic mechanism plotted against the MK concentration. Open squares present the result of assay for the haptotactic mechanism in which MK was pre-coated on the lower surface of the filter; filled diamonds the result of assay for the chemotactic mechanism in which MK was pre-coated on both surfaces of the filter; open circles the results of negative control in which MK was pre-coated on the upper surface of the filter. After 30-minute incubation, the number of neutrophils migrated to the lower surface of the filter was counted. A value plotted represents a mean value of the migrated cell number per optical field.

Best Mode for Carrying out the Invention

[0026] Examples of the present invention are described below, but are not construed to limit the scope of this invention.

Example 1

Detection of midkine (MK) by ELISA

5 **[0027]** Samples of synovial fluid were collected by aspiration from patients (aged 26 to 72; average age 52 years) with inflammatory synovitis of OA or RA. MK in the sample of synovial fluid was assayed by ELISA (Muramatsu, H. et al., J. Biochem. 119: 1171-1175, 1996). MK 10 was not detected in any synovial fluid samples derived from the three healthy subjects, while MK was detected in all the samples derived from six patients with RA (Fig. 1; 62 to 10,000 pg/ml of the MK concentration). A significant amount of MK was also detected in four out of six 15 samples each derived from different OA patients (Fig. 1; below the detection limit to 1225 pg/ml). The results indicate that MK levels in synovial fluid correlate significantly with inflammatory states in synovitis.

Example 2

Immunohistochemical detection of MK

[0028] Synovial tissues were obtained from the entire 25 knee parts of three RA patients and two OA patients. All the biopsy samples contained hyperplastic inflammatory periosteum tissues which are characterized histologically by propagation of lining cells of the synovial membrane, extensive infiltration of lymphocytes and macrophages, 30 and vigorous angiogenesis. Immunohistochemical examination was carried out using the method of Muramatsu et al. (Muramatsu, H., et al., Dev. Biol. 159: 392-402, 1993). The biopsy samples were fixed with neutrally buffered formalin, embedded in paraffin, and sliced into sections 35 with 5- μ m thickness. The sections were incubated with anti-human MK antibody (15 mg/ml) in PBS containing 0.2% bovine serum albumin and 2% normal goat serum at 4°C overnight. The anti-human MK antibody was prepared by the method of Muramatsu et al. (Muramatsu, H., et al., J. Biochem. 119: 1171-1175, 1996) using a rabbit immunized with chemically synthesized human MK purchased from Peptide Institute, Inc. Control sections were incubated with PBS containing 2% bovine serum albumin or normal rabbit serum. The sample and 40 control sections were incubated with biotinylated goat anti-rabbit antibody (diluted to antibody:PBS = 1:250) and washed. The sections were then incubated with an avidin-biotin peroxidase conjugate (Vector Laboratories Inc., Burlingame, U.S.A.), followed by adding 3-amino-45 9-ethylcarbazole (AEC) containing 1% hydrogen peroxide and incubating the mixture to develop color.

[0029] Using anti-MK antibody, the samples from two 50 patients with RA were stained broadly in a region between the synovial parietal cells and neogenetic vessels (Fig. 2A). Interestingly, the synovial parietal cells (Fig. 2B) and the capillary endothelial cells (Fig. 2C) were strongly stained by MK. The sample from one RA patient was not strongly stained as compared with samples from

the other patients. This can be explained that the states of the conditions were not active in this patient. The degree of immunological staining of two cases of OA with the inflammatory synovial with the anti-MK antibody was comparable to the inflammatory synovial membrane of RA patients. Samples of the synovial membrane from healthy subjects were not available. Instead the biopsy samples free of inflammatory synovial membrane from patients who underwent artificial joint replacement were examined. These samples were not immunologically stained.

Example 3

Detection of MK by Western blot analysis

[0030] The synovial tissue extract was subjected to Western blot analysis. The samples were electrophoresed in an SDS-polyacrylamide gel by the method of Laemmli (Laemmli, U. K., *Nature* 227: 680-685, 1970), and proteins in the gel were transferred onto a nitrocellulose membrane by the method of Towin et al. (Towin, H. et al., *Proc. Natl. Acad. Sci. USA.* 76: 4350-4354, 1979). The nitrocellulose membrane was incubated in Dulbecco's phosphate-buffered saline (PBS) containing 5% skim milk at 4°C overnight, and then incubated with diluted anti-human MK antibody (diluted to 20 mg/ml with a 5% skim milk solution) at room temperature for 2 hours. The nitrocellulose membrane was then washed with PBS containing 0.1% Tween 20, incubated with affinity-purified anti-rabbit IgG-horseradish peroxidase conjugate (Jackson Immunoresearch Laboratories, Inc. Baltimore, USA), and stained with 4-chloro-1-naphthol.

[0031] MK was detected at a high level in the extract of active inflammatory synovial membrane from an OA patient (Fig. 3, lane 1). While the inflammatory site of active sinovitis in an RA patient contained MK at a moderate level (Fig. 3, lane 2), the MK level was low at a non-active inflammation site of the same patient (Fig. 3, lane 3). MK was not detected in samples derived from patients who underwent artificial joint replacement and patients who were not affected with inflammatory synovitis (Fig. 3, lane 4). The immunoreactive substance was thus confirmed to be MK. Furthermore, the correlation of the expression level of MK with the severity of inflammation, which had been found by immunohistochemistry, was also identified by Western blot analysis.

Example 4

Effect of MK on migration of human neutrophils

[0032] Chemotaxis of neutrophils induced by MK was assayed in order to evaluate the role of MK in leukocyte mobilization at earlier stages of the inflammation reaction. Neutrophils were separated from peripheral blood of healthy subjects by specific gravity centrifugation in Ficoll-Hypaque (Venaille, T. J. et al., *Scand. J. Clin. Lab.*

Invest. 54: 385-391, 1994). The collected cells were rinsed with PRMI1640 culture medium and suspended in the same medium supplemented with 10% human serum with the blood type AB to a cell concentration of 2.5×10^6 cells/ml. Neutrophilic migration induced by MK was measured with Chemotaxicell (Kurabo Co., Ltd., Osaka, Japan), which was used as a top chamber. Chemotaxicell is identical to the Boyden chamber equipped with a polycarbonate filter. A 24-well culture plate (3047, Falcon) was used as a bottom chamber. MK diluted with RPMI1640 culture medium supplemented with 10% human serum with the blood type AB were added to wells of the 24-well plate. Subsequently, neutrophils (5×10^5 cells) suspended in the same culture medium were placed in Chemotaxicell. The chamber was incubated in a 5% CO₂ incubator in a humid atmosphere at 37°C for 3 hours. The cells migrated through the filter with 5-μm pores were fixed with 100% ethanol, stained, and then counted under a microscope (Olympus AX80, 400 magnifications). In each assay neutrophils were counted in 10 optical fields. Each sample was assayed in triplicate. The data were represented as average number±standard deviation. This experiment revealed that MK in the bottom chamber stimulates the migration of neutrophils in the top chamber (Fig. 4). The optimal concentration of MK to induce neutrophilic migration was 10 ng/ml (level of significance: $p<0.01$) (Fig. 4).

[0033] Checkerboard analysis (Zigmond, S.H., and Hirsch, J.G., *J. Exp. Med.* 137:387-410, 1973) was performed to clarify whether the MK-dependent neutrophilic migration is governed by an oriented movement with recognizing the concentration gradient of the chemotactant factor (chemotaxis), or by a random movement (chemical motility). The result is illustrated in Fig. 5.

[0034] It is obvious from the data shown in the figure that an increased number of neutrophils migrates through the filter when the MK concentration gradient is made in such a manner that the MK concentration is higher at the bottom chamber and lower at the top chamber, indicating that MK functions as a chemotactant factor.

Example 5

Mechanism of MK-dependent chemotaxis

[0035] Acquisition of the motility of cells is recognized as an adhesion-dependent event (Timothy, A.S., *Cell* 76: 301-314, 1994). MK binds strongly to syndecan (Mitsiadis, T. A. et al., *Development* 121: 37-51, 1995; and Kojima, T. et al., *J. Biol. Chem.* 271(10): 5914-5920, 1996) that belongs to the family of cell surface heparan sulfate proteoglycan (Elenius, K. et al., *J. Cell. Biol.* 114: 585-595, 1991). The ability of matrix-bound MK to enhance the neutrophilic migration was examined. Specifically, the assay for the haptotactic mechanism was carried out by the method of Rot (Rot, A., *Eur. J. Immunol.* 23: 303-306, 1993) to determine whether MK functions in the free form (chemotactic mechanism) or in the matrix-

bound form (haptotactic mechanism).

[0036] As the initial step in the assay for the haptotactic mechanism, the lower surface of the filter was pre-coated with MK by adding MK (1 to 100 ng/ml) in the bottom wells, and the corresponding top wells were filled with RPMI1640 medium to establish positive haptotactic gradients of MK.

[0037] In another set for the negative control assay, the upper surface of the filter were pre-coated with MK by adding MK (1 to 100 ng/ml) in the top wells, the corresponding bottom wells were filled with RPMI1640 medium, thereby establishing negative haptotactic gradients.

[0038] In the assay for the chemotactic mechanism, both top and bottom wells were filled with RPMI1640 medium (chemotactic gradients).

[0039] Each well was incubated at 37°C for 20 minutes, and the Chemotaxicell composed of the top chamber and the polycarbonate filter was washed well with RPMI solution to remove unbound (free) MK molecules.

[0040] As the second step, both top and bottom wells were filled with RPMI solution containing 10% serum with the blood type AB in the assays for the haptotactic mechanism and the negative control. In the assay for the chemotactic mechanism, MK (1 to 100 ng/ml) was added to the bottom chamber.

[0041] Neutrophils (5×10^5) were placed in the top wells in each set prepared in the second step. The wells were incubated at 37°C for 30 minutes, and the motility of neutrophils was measured by counting the neutrophils migrated through the filter. In each assay neutrophils were counted in 10 optical fields. Each sample was assayed in triplicate. The data were represented as the number of the migrated cells \pm standard deviation.

[0042] In the assay for the haptotactic mechanism, the filter-bound MK stimulated neutrophilic migration even at a low concentration of MK (1 ng/ml; level of significance, $p<0.01$) during the short period (30 minutes) of incubation (Fig. 6, open squares). In contrast, the neutrophilic migration was not stimulated after a 30-minute incubation in the assay for the chemotactic mechanism (Fig. 6, filled diamonds) as well as in the negative control assay (Fig. 6, open circles). These results indicate that the midkine-stimulated neutrophilic migration was based on the haptotactic mechanism.

Industrial Applicability

[0043] The invention enables treatment of neutrophilic functional disorders by stimulating neutrophilic migration or treatment of inflammatory diseases by inhibiting neutrophilic migration.

Claims

1. Use of midkine for the preparation of a pharmaceutical composition for treating a neutrophilic functional

disorder.

2. The use of claim 1, wherein the treatment is accomplished by controlling a neutrophilic function.
- 5 3. The use of claim 2, wherein the neutrophilic function is migration.
- 10 4. The use of claim 3, wherein the migration is based on chemotaxis.
- 15 5. The use of claim 4, wherein the chemotaxis is based on the haptotactic mechanism.
- 20 6. The use of claim 1, wherein the neutrophilic functional disorder is the lazy-leukocyte syndrome.
- 25 7. The use of claim 1, wherein the pharmaceutical composition further comprises another factor(s) which enhance(s) neutrophilic function, wherein the factor is selected from the group consisting of G-CSF, GM-CSF, IL-8 and M-CSF.
- 30 8. Use of - an anti-midkine antibody for the preparation of a pharmaceutical composition for treating an inflammatory disease.
- 35 9. Use according to claim 8, wherein the inflammatory disease is rheumatoid arthritis or osteoarthritis.
- 40 10. A method for stimulating neutrophilic chemotaxis *in vitro* using midkine or using an agent comprising midkine as an active ingredient.
- 45 11. The method of claim 10, wherein the agent further comprises other factor(s) which enhance(s) neutrophilic function, wherein the factor is selected from the group consisting of G-CSF, GM-CSF, IL-8 and M-CSF.

Patentansprüche

1. Verwendung von Midkine für die Herstellung eines Arzneimittels zur Behandlung einer Neutrophilen-Funktionsstörung.
- 45 2. Verwendung nach Anspruch 1, wobei die Behandlung durch Regulieren einer Neutrophilen-Funktion zustande kommt.
- 50 3. Verwendung nach Anspruch 2, wobei die Neutrophilen-Funktion Migration ist.
- 55 4. Verwendung nach Anspruch 3, wobei die Migration auf Chemotaxis basiert.
5. Verwendung nach Anspruch 4, wobei die Chemota-

xis auf dem haptotaktischen Mechanismus basiert.

6. Verwendung nach Anspruch 1, wobei die Neutrophilen-Funktionsstörung das träge Leukozyten-Syndrom ist. 5

7. Verwendung nach Anspruch 1, wobei das Arzneimittel ferner einen anderen (andere) Faktor (Faktoren) umfasst, der (die) die Neutrophilen-Funktion steigert (steigern), wobei der Faktor aus G-CSF, GM-CSF, IL-8 und M-CSF ausgewählt ist.

8. Verwendung eines Anti-Midkine-Antikörpers für die Herstellung eines Arzneimittels zur Behandlung einer entzündlichen Erkrankung. 10

9. Verwendung nach Anspruch 8, wobei die entzündliche Erkrankung rheumatoide Arthritis oder Osteoarthritis ist.

10. Verfahren zur Stimulierung der Neutrophilen-Chemotaxis *in vitro* unter Verwendung von Midkine oder unter Verwendung eines Mittels, das Midkine als einen Wirkstoff umfasst. 15

11. Verfahren nach Anspruch 10, wobei das Mittel ferner einen anderen (andere) Faktor (Faktoren) umfasst, der (die) die Neutrophilen-Funktion steigert (steigern), wobei der Faktor aus G-CSF, GM-CSF, IL-8 und M-CSF ausgewählt ist. 20

25

12. Utilisation de midkine pour la préparation d'une composition pharmaceutique pour traiter un trouble fonctionnel des neutrophiles. 30

13. Utilisation de la revendication 1, dans laquelle le traitement est accompli en contrôlant une fonction des neutrophiles. 35

14. Utilisation de la revendication 2, dans laquelle la fonction des neutrophiles est la migration. 40

15. Utilisation de la revendication 3, dans laquelle la migration est basée sur le chimiotactisme. 45

16. Utilisation de la revendication 4, dans laquelle le chimiotactisme est basé sur le mécanisme haptotactique. 50

17. Utilisation de la revendication 1, dans laquelle le trouble fonctionnel des neutrophiles est le syndrome des leucocytes paresseux. 55

18. Utilisation de la revendication 1, dans laquelle la composition pharmaceutique comprend en outre un ou plusieurs autres facteurs qui activent une fonction des neutrophiles, le ou les facteurs étant choisis dans l'ensemble consistant en G-CSF, GM-CSF, IL-8 et M-CSF.

19. Utilisation d'un anticorps anti-midkine pour la préparation d'une composition pharmaceutique pour traiter une maladie inflammatoire. 60

20. Utilisation selon la revendication 8, dans laquelle la maladie inflammatoire est la polyarthrite rhumatoïde ou l'arthrose. 65

21. Procédé pour stimuler *in vitro* le chimiotactisme des neutrophiles en utilisant la midkine ou en utilisant un agent comprenant la midkine comme ingrédient actif. 70

22. Procédé de la revendication 10, dans lequel l'agent comprend en outre un ou plusieurs autres facteurs qui améliorent une fonction des neutrophiles, le ou les facteurs étant choisis dans l'ensemble consistant en G-CSF, GM-CSF, IL-8 et M-CSF. 75

23. Verfahren zur Stimulierung der Neutrophilen-Chemotaxis *in vitro* unter Verwendung von Midkine oder unter Verwendung eines Mittels, das Midkine als einen Wirkstoff umfasst. 80

24. Verfahren nach Anspruch 10, wobei das Mittel ferner einen anderen (andere) Faktor (Faktoren) umfasst, der (die) die Neutrophilen-Funktion steigert (steigern), wobei der Faktor aus G-CSF, GM-CSF, IL-8 und M-CSF ausgewählt ist. 85

25. Utilisation de midkine pour la préparation d'une composition pharmaceutique pour traiter un trouble fonctionnel des neutrophiles. 90

26. Utilisation de la revendication 1, dans laquelle le traitement est accompli en contrôlant une fonction des neutrophiles. 95

27. Utilisation de la revendication 2, dans laquelle la fonction des neutrophiles est la migration. 100

28. Utilisation de la revendication 3, dans laquelle la migration est basée sur le chimiotactisme. 105

29. Utilisation de la revendication 4, dans laquelle le chimiotactisme est basé sur le mécanisme haptotactique. 110

30. Utilisation de la revendication 1, dans laquelle le trouble fonctionnel des neutrophiles est le syndrome des leucocytes paresseux. 115

31. Utilisation de la revendication 1, dans laquelle la composition pharmaceutique comprend en outre un ou plusieurs autres facteurs qui activent une fonction des neutrophiles, le ou les facteurs étant choisis dans l'ensemble consistant en G-CSF, GM-CSF, IL-8 et M-CSF. 120

Revendications

1. Utilisation de midkine pour la préparation d'une composition pharmaceutique pour traiter un trouble fonctionnel des neutrophiles. 35

2. Utilisation de la revendication 1, dans laquelle le traitement est accompli en contrôlant une fonction des neutrophiles. 40

3. Utilisation de la revendication 2, dans laquelle la fonction des neutrophiles est la migration. 45


4. Utilisation de la revendication 3, dans laquelle la migration est basée sur le chimiotactisme. 50

5. Utilisation de la revendication 4, dans laquelle le chimiotactisme est basé sur le mécanisme haptotactique. 55

6. Utilisation de la revendication 1, dans laquelle le trouble fonctionnel des neutrophiles est le syndrome des leucocytes paresseux. 60

7. Utilisation de la revendication 1, dans laquelle la composition pharmaceutique comprend en outre un ou plusieurs autres facteurs qui activent une fonction des neutrophiles, le ou les facteurs étant choisis dans l'ensemble consistant en G-CSF, GM-CSF, IL-8 et M-CSF. 65

Figure 1



Diagnosis

Figure 2




Figure 3




Figure 4




Figure 5

		MK concentration (ng/ml) in top chamber			
		0	1	10	100
MK concentration (ng/ml) in bottom chamber	0	3.2±0.5	2.1±0.4	3.7±0.5	2.8±0.3
	1	5.7±0.6	2.6±0.6	4.5±0.7	3.5±0.4
	10	8.3±1.2	5.5±0.7	4.7±0.5	2.6±0.4
	100	6.8±0.5	6.9±0.6	6.9±0.7	5.8±0.9

Figure 6

